Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
News & Events

Press Releases

Upcoming Events

Media Contact:
Nancy Pecota
Chief Financial Officer
Assistant: Rita Mateo
Phone: 510-265-8800
E-mail: investor@aradigm.com

Latest News

FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic
[20MAY14
]

Aradigm Announces First Quarter 2014 Financial Results
[14MAY14
]

Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-3)
[30APR14
]

Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference
[15APR14
]

Aradigm Announces Fourth Quarter 2013 and Full Year Financial Results
[04FEB14
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2014 on February 11
[04FEB14
]

Aradigm to Present at Biotech Showcase 2014 on January 14
[28JAN14]

Aradigm Announces Appointment of Dr. Juergen Froehlich as Chief Medical Officer
[19NOV13
]

Aradigm Announces Third Quarter 2013 Financial Results
[28OCT13
]

Aradigm Announces Changes to its Board of Directors
[18SEP13
]

Sigma-Tau PharmaSource, Inc. and Aradigm Corporation Sign Manufacturing Agreement for the Clinical and Commercial Supply of Pulmaquin
[16SEP13
]

Aradigm to Present at the Stifel Nicolaus 2013 Healthcare Conference
[09SEP13
]

Grifols and Aradigm Corporation Complete the Closing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin®
[28AUG13
]

Aradigm Announces Second Quarter 2013 Financial Results
[08AUG13
]

Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Pulmaquin and Lipoquin
[07AUG13
]

Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commercialize Pulmaquin
[16JUL13
]

Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™
[21MAY13
]

Aradigm Announces First Quarter 2013 Financial Results
[14MAY13
]

Aradigm Announces Fourth Quarter 2012 and Full Year Financial Results
[26MAR12
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12
[06FEB12
]

Aradigm to Present at Biotech Showcase 2013 on January 9
[12DEC12
]

Aradigm Announces Private Placement for $6 Million
[12DEC12
]

UK Scientists Report on Efficacy of Aradigm's Lipoquin™ Against Pneumonic Plague
[10DEC12
]

Aradigm Announces Third Quarter 2012 Financial Results
[08NOV12
]

Virginia Commonwealth University Scientists Report Anti-Inflammatory Effect of Aradigm's Inhaled Liposomal Ciprofloxacin
[18OCT12
]

UK Scientists Report Successful Testing of Aradigm's Inhaled Liposomal Ciprofloxacin in Q Fever
[20SEP12
]

New U.S. Composition of Matter Patent for Aradigm's Pulmaquin™ and Lipoquin™ Provides Protection Until 2031
[18SEP12
]

Aradigm Patent Protection for Smoking Cessation is Extended with Issuance of a Method of Treatment Patent
[05SEP12
]

Aradigm to Participate in FDA Workshop on Non-Cystic Fibrosis Bronchiectasis
[30AUG12
]

Aradigm to Present at the Stifel Nicolaus 2012 Healthcare Conference
[29AUG12
]

Aradigm Announces Second Quarter 2012 Financial Results
[09AUG12
]

Aradigm Announces First Quarter 2012 and Full Year Financial Results
[11MAY12
]

Aradigm Announces Fourth Quarter 2011 and Full Year Financial Results
[27MAR12
]

Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis
[12MAR12
]

US Patent Protection for Pulmaquin™ Is Extended with Issuance of a Composition of Matter Patent
[21FEB12
]

Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13
[08FEB12
]

Aradigm to Present at Biotech Showcase 2012 on January 9
[05JAN12
]

Aradigm Selects Pulmaquin™ for Phase 3 Development and Announces Issuance of Its First U.S. Patent Covering Inhaled Ciprofloxacin Formulations
[07DEC11
]

Aradigm Announces Third Quarter 2011 Financial Results
[10NOV11
]

Aradigm to Present at the 10th Annual BIO Investor Forum on October 26
[20OCT11
]

Aradigm Presents Additional Analyses of the Clinical Results From ORBIT-1 and ORBIT-2 Trials of Inhaled Ciprofloxacin at the 2011 European Respiratory Society (ERS) Annual Congress
[21SEP11
]

Aradigm to Present at Rodman & Renshaw Annual Global Investment Conference
[07SEP11
]

Aradigm Announces Second Quarter 2011 Financial Results
[09AUG11
]

Aradigm Announces Private Placement for $4.75 Million
[06JUL11
]

Aradigm Enters $8.5 Million Royalty Financing Agreement With PBS Capital Management LLC
[22JUN11
]

Aradigm Reports Successful ORBIT-1 Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
[16JUN11
]

Aradigm Receives FDA Orphan Drug Designation for Ciprofloxacin for Inhalation in Bronchiectasis
[06JUN11
]

Aradigm Announces First Quarter 2011 Financial Results
[12MAY11
]

Aradigm to Present Additional ORBIT-2 Clinical Trial Results at Respiratory Drug Delivery Europe 2011 Conference
[03MAY11
]

Aradigm Announces Fourth Quarter 2010 and Full Year Financial Results
[24MAR11
]

Aradigm Completes Enrollment in Phase 2b Study of Inhaled Ciprofloxacin for the Management of Respiratory Infections in Bronchiectasis
[22MAR11
]

Aradigm to Present at ROTH Capital Partners 23rd Annual OC Growth Stock Conference
[10MAR11
]

Aradigm to Present at the 13th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference
[10FEB11
]

SUMAVEL DosePro Receives Marketing Approval in Germany and the United Kingdom
[11JAN11
]

Aradigm to Report Expanded Results from Successful Six-Month Phase 2b Bronchiectasis Study at Biotech Showcase 2011
[06JAN11
]

SUMAVEL DosePro is Granted First European Approval
[07DEC10
]

Aradigm Announces Third Quarter 2010 Financial Results
[11NOV10
]

Aradigm Appoints Tamar Howson to Board of Directors
[04NOV10
]

Aradigm Awarded Three Therapeutic Discovery Tax Credit Grants Totaling Over $733,000 for Inhaled Liposomal Ciprofloxacin Program
[02NOV10
]

Aradigm Reports Successful Phase 2b Bronchiectasis Study with Inhaled Liposomal Ciprofloxacin
[20OCT10
]

Aradigm to Present at the 9th Annual BIO Investor Forum on )ctober 6
[04OCT10
]

Aradigm CEO Igor Gonda to Be Featured Guest Interview on StockGoodies.com Radio on September 30
[30SEP10
]

Aradigm Announces Exercise of Warrants for Proceeds of Approximately $891,000
[23SEP10
]

Aradigm Closes Equity for Debt Transaction with Novo Nordisk A/S
[20SEP10
]

Aradigm Presents Results Supporting Once-Daily Dosing With Its Inhaled Liposomal Ciprofloxacin Formulations at the 2010 European Respiratory Society (ERS) Annual Congress
[17SEP10
]

Aradigm Announces Second Quarter 2010 Financial Results
[12AUG10
]

Aradigm Announces Equity for Debt Transaction with Novo Nordisk
[02AUG10
]

Aradigm Announces Private Placement for $5 Million
[21JUN10
]

Aradigm Presents at the 2010 International Conference of the American Thoracic Society
[17MAY10
]

Aradigm Announces First Quarter 2010 Financial Results
[13MAY10
]

Aradigm Receives FDA Clearance for Clinical Trial of Inhaled Liposomal Ciprofloxacin in Pediatric Patients With Cystic Fibrosis
[05MAY10
]

Aradigm Completes Enrollment and Doses Last Patient in Long Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[25MAR10
]

Aradigm Announces Fourth Quarter 2009 and Full Year Financial Results
[23MAR10
]

Aradigm Doses First Patient in Its Second Phase 2b Clinical Trial of Inhaled Liposomal Ciprofloxacin in Bronchiectasis Patients
[23FEB10
]

Aradigm Receives $4 Million Milestone Payment Upon First Commercial Sale of SUMAVEL* DosePro*
[04FEB10
]

Aradigm to Present at Biotech Showcase 2010 on January 12
[06JAN10
]

Aradigm to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
[10DEC09]

Aradigm Doses First Patient in Long-Term Phase 2 Study of a Novel Inhaled Ciprofloxacin Formulation for the Management of Respiratory Infections in Bronchiectasis
[16NOV
09]

Aradigm Announces Third Quarter 2009 Financial Results
[14SEP
09]

Aradigm to Present at the 8th Annual BIO Investor Forum on October 28
[22OCT
09]

Aradigm Presents Data Demonstrating Significant Antibacterial Concentrations and Effects in Non-Cystic Fibrosis Bronchiectasis Patients Following Administration of its Once-Daily Inhaled Liposomal Ciprofloxacin
[14SEP
09]

Aradigm Announces Second Quarter 2009 Financial Results
[06AUG
09]

Aradigm Receives Orphan Drug Designation for Inhaled Liposomal Ciprofloxacin to Treat Cystic Fibrosis in Europe
[05AUG
09]

Zogenix Announces Exclusive Co-Promotion Agreement in U.S. for Sumavel(TM) DosePro(TM)
[04AUG
09]

Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
[23JUL
09]

Zogenix Obtains Approval in U.S. for Sumavel(TM) DosePro(TM)
[16JUN
09]

Upcoming Events
For a listing of Upcoming Events click here.

 

 

 

 

 

 

 

CONTACT NEWS & EVENTS LEGAL SITE MAP ©2013 Aradigm Corporation. All Rights Reserved.